| Name | Acrivastine |
| Description | Acrivastine (Acrivastin) is a short-acting histamine 1 receptor antagonist. |
| In vivo | Acrivastine, administered typically at 8mg thrice daily, is a highly effective and well-tolerated antihistamine for managing chronic urticaria and allergic rhinitis, offering minimal drowsiness compared to clemastine and similar adverse effect profiles to placebo or terfenadine. It demonstrates superior efficacy over placebo and comparability to clemastine, hydroxyzine, chlorpheniramine, cyproheptadine, and terfenadine in treating histamine-related dermatoses. Both 4mg and 8mg doses notably improve symptoms of seasonal allergic rhinitis, including sneezing, runny nose, and overall discomfort, with the 8mg dose additionally reducing watery eyes and itchy throat symptoms. Therefore, acrivastine is recognized as both effective and well-tolerated in treating seasonal allergic rhinitis. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 1 mg/mL (2.87 mM), Sonication is recommended. DMSO : 5 mg/mL (14.35 mM), Sonication is recommended.
|
| Keywords | Inhibitor | inhibit | HistamineReceptor | Histamine Receptor | H1 receptor | Acrivastine |
| Inhibitors Related | Undecane | Betahistine mesylate | Histamine dihydrochloride | Meclizine dihydrochloride | Lidocaine | Famotidine | Sodium butanoate | Nizatidine | Alginic acid | Mianserin hydrochloride | Trazodone hydrochloride | Doxepin hydrochloride |
| Related Compound Libraries | FDA-Approved & Pharmacopeia Drug Library | Bioactive Compound Library | Pain-Related Compound Library | Membrane Protein-targeted Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Cancer Approved Drug Library | FDA-Approved Drug Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Drug Library |